A Phase 1 interventional study of Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII) in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 11 sites in United States. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-24.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 1, and was the 7th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 2 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 1 started in 2008.
This study's enrollment of 52 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
47 studies in Hemophilia A by Takeda: none open now, 1 under way, none of them phase 3. Of 46 finished, 27 (59%) have results posted.
Among the 47 studies in Hemophilia A by Takeda, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2008, is one of 4 in phase 1, and was the 14th registered.
Takeda’s Hemophilia A studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 47 in Hemophilia A:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the pharmacokinetics and safety of Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) reconstituted in 2 mL sterile water for injection (SWFI) and compare with those of rAHF-PFM reconstituted in 5 mL of SWFI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADVATE reconstituted in 2 mL sterile water for infusion
Biological: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
ADVATE reconstituted in 5 mL sterile water for infusion
Biological: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
Also known as: ADVATE
Area Under the Curve
Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Total Area Under the Curve
Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Adjusted in Vivo Incremental Recovery
Increase in factor VIII concentration from pre- to post-infusion
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion
Terminal Half-life
Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Weight-Adjusted Clearance
Computed as the weight-adjusted dose divided by total AUC
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Mean Residence Time
Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Volume of Distribution at Steady State
Computed as weight-adjusted clearance \* mean residence time
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Maximum Plasma Concentration
Maximal factor VIII concentration post-infusion
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Number and Severity of Infusion Site Reactions
Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).
Time frame: Within 5 minutes pre-infusion up to 24 hours post-infusion
Infusion Site Pain
Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).
Time frame: Within 5 minutes post-infusion up to 24 hours post-infusion
Enrollment was conducted in the United States at 11 sites. Two cohorts were recruited (adolescent/adults aged ≥12 to ≤65 years and pediatrics aged ≥2 to \<12 years).
| Milestone | Adolescents/Adults - 2 mL Then 5 mL | Adolescents/Adults - 5 mL Then 2 mL | Pediatrics - 2 mL Then 5 mL | Pediatrics - 5 mL Then 2 mL |
|---|---|---|---|---|
| Started | 9 | 18 | 11 | 4 |
| Completed | 9 | 17 | 11 | 4 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Milestone | Adolescents/Adults - 2 mL Then 5 mL | Adolescents/Adults - 5 mL Then 2 mL | Pediatrics - 2 mL Then 5 mL | Pediatrics - 5 mL Then 2 mL |
|---|---|---|---|---|
| Started | 9 | 17 | 11 | 4 |
| Completed | 9 | 17 | 10 | 4 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method
| IU*h/dL | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Area Under the Curve | 1257.20 ± 380.60 | 1297.42 ± 487.57 |
Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model
| IU*h/dL | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Total Area Under the Curve | 1357.60 ± 436.24 | 1368.12 ± 553.21 |
Increase in factor VIII concentration from pre- to post-infusion
| IU/dL:IU/kg | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL | Pediatrics - 2 mL | Pediatrics - 5 mL |
|---|---|---|---|---|
| Adjusted in Vivo Incremental Recovery | 1.87 ± 0.34 | 1.88 ± 0.40 | 1.33 ± 0.36 | 1.66 ± 0.25 |
Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
| hours | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Terminal Half-life | 12.54 ± 3.80 | 12.50 ± 2.89 |
Computed as the weight-adjusted dose divided by total AUC
| mL/(kg*h) | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Weight-Adjusted Clearance | 3.85 ± 0.95 | 3.81 ± 1.20 |
Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods
| hours (h) | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Mean Residence Time | 14.79 ± 5.24 | 14.34 ± 4.27 |
Computed as weight-adjusted clearance \* mean residence time
| dL/kg | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Volume of Distribution at Steady State | 0.54 ± 0.13 | 0.51 ± 0.13 |
Maximal factor VIII concentration post-infusion
| IU/dL | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL |
|---|---|---|
| Maximum Plasma Concentration | 102.77 ± 19.35 | 106.46 ± 17.95 |
Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).
| Participants | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL | Pediatrics - 2 mL | Pediatrics - 5 mL |
|---|---|---|---|---|
| Pain- Mild (Grade 1) | 0 | 0 | 0 | 0 |
| Pain- Moderate (Grade 2) | 0 | 0 | 0 | 0 |
| Pain- Severe (Grade 3) | 0 | 0 | 0 | 0 |
| Pain- Potentially Life Threatening (Grade 4) | 0 | 0 | 0 | 0 |
| Tenderness- Mild (Grade 1) | 0 | 0 | 0 | 0 |
| Tenderness- Moderate (Grade 2) | 0 | 0 | 0 | 0 |
| Tenderness- Severe (Grade 3) | 0 | 0 | 0 | 0 |
| Tenderness- Potentially Life Threatening (Grade 4) | 0 | 0 | 0 | 0 |
| Erythema- Mild (Grade 1) | 0 | 0 | 0 | 0 |
| Erythema- Moderate (Grade 2) | 0 | 0 | 0 | 0 |
| Erythema- Severe (Grade 3) | 0 | 0 | 0 | 0 |
| Erythema- Potentially Life Threatening (Grade 4) | 0 | 0 | 0 | 0 |
| Induration- Mild (Grade 1) | 0 | 0 | 1 | 0 |
| Induration- Moderate (Grade 2) | 0 | 0 | 0 | 0 |
| Induration- Severe (Grade 3) | 0 | 0 | 0 | 0 |
| Induration- Potentially Life Threatening (Grade 4) | 0 | 0 | 0 | 0 |
| Bruising- Mild (Grade 1) | 0 | 0 | 1 | 0 |
| Bruising- Moderate (Grade 2) | 0 | 0 | 0 | 0 |
| Bruising- Severe (Grade 3) | 0 | 0 | 0 | 0 |
| Bruising- Potentially Life Threatening (Grade 4) | 0 | 0 | 0 | 0 |
Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).
| Scores on a scale | Adolescents/Adults - 2 mL | Adolescents/Adults - 5 mL | Pediatrics at Least 5 Years of Age - 2 mL | Pediatrics at Least 5 Years of Age - 5 mL |
|---|---|---|---|---|
| Within 5 minutes (immediately) after infusion | 0 (0 to 12) | 0 (0 to 27) | 8 (0 to 37) | 4 (0 to 61) |
| 60 ± 5 minutes after infusion | 0 (0 to 3) | 0 (0 to 4) | 2.5 (0 to 66) | 1 (0 to 7) |
| 6 hours ± 30 minutes after infusion | 0 (0 to 3) | 0 (0 to 2) | 0 (0 to 8) | 0 (0 to 4) |
| 24 hours after infusion | 0 (0 to 2) | 0 (0 to 3) | 0 (0 to 8) | 0 (0 to 2) |
Collected over During course of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adolescents/Adults | — | 0/27 (0%) | 1/27 (3.7%) |
| Pediatrics | — | 1/15 (6.7%) | 10/15 (66.7%) |
| Event | Adolescents/Adults | Pediatrics |
|---|---|---|
| PyrexiaGeneral disorders | 0/27 | 1/15 |
| Event | Adolescents/Adults | Pediatrics |
|---|---|---|
| ContusionInjury, poisoning and procedural complications | 1/27 | 5/15 |
| Arthropod biteInjury, poisoning and procedural complications | 1/27 | 2/15 |
| Allergy to arthropod stingImmune system disorders | 0/27 | 1/15 |
| Catheter thrombosisGeneral disorders | 0/27 | 1/15 |
| Conjunctival hemorrhageEye disorders | 0/27 | 1/15 |
| Ear infectionInfections and infestations | 0/27 | 1/15 |
| HemarthrosisMusculoskeletal and connective tissue disorders | 0/27 | 1/15 |
| Injection site hematomaGeneral disorders | 0/27 | 1/15 |
| Injection site swellingGeneral disorders | 0/27 | 1/15 |
| Joint range of motionMusculoskeletal and connective tissue disorders | 0/27 | 1/15 |
| Age, Continuous(years) | Treated Participants |
|---|---|
| Pediatrics | 6 ± 3 |
| Adolescents/Adults | 26 ± 10 |
| Age, Customized(Participants) | Treated Participants |
|---|---|
| ≥2 to <12 years (Number Pediatrics) | 15 |
| ≥12 to <16 years (Number Adolescents) | 3 |
| ≥16 to 65 years (Number Adults) | 24 |
| Sex: Female, Male(Participants) | Treated Participants |
|---|---|
| Female | 0 |
| Male | 42 |
| Region of Enrollment(Participants) | Treated Participants |
|---|---|
| United States | 42 |
Ran from Aug 2008 to primary completion in Oct 2009, 14 months.
Results were first posted in Jul 2011, 1 year 8 months after primary completion.
Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 14 months is above that.
Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Antihemophilic factor, human recombinant